You just read:

Novartis receives Health Canada approval for the combination therapy of Tafinlar® (dabrafenib) plus Mekinist® (trametinib) for adjuvant treatment of patients with BRAF V600 mutation melanoma(i)

News provided by

Novartis Pharmaceuticals Canada Inc.

Nov 01, 2018, 10:45 ET